SCHEMBL31146064

SCHEMBL31146064

COc1ccc2[nH]c(=O)c(CC(=O)N[C@@H](C)c3ccc(F)cc3F)cc2c1C#N

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IDH1 O75874 5/20 0.42
▸ GPR139 Q6DWJ6 5/20 0.37
▸ P2RX7 Q99572 3/20 0.37
▸ KMT2A Q03164 1/20 0.36
▸ NTRK1 P04629 1/20 0.36
▸ ADORA1 P30542 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31146157 0.89 GPR139 (0.39) IDH1GPR139KMT2AADORA1ALDH1A1
SCHEMBL31145976 0.87 GPR139 (0.39) IDH1GPR139KMT2AADORA1ALDH1A1
SCHEMBL31145975 0.85 GPR139 (0.39) IDH1GPR139P2RX7ALDH1A1CYP1A2
SCHEMBL31146104 0.80 GPR139 (0.40) IDH1GPR139ADORA1ALDH1A1KDM4E
SCHEMBL31146058 0.78 GPR139 (0.42) IDH1GPR139ADORA1ALDH1A1KDM4E
SCHEMBL31146050 0.77 GPR139 (0.42) IDH1GPR139P2RX7ALDH1A1KDM4E
SCHEMBL31145932 0.76 GPR139 (0.41) IDH1GPR139P2RX7ALDH1A1KDM4E
SCHEMBL31146046 0.76 GPR139 (0.40) IDH1GPR139ADORA1ALDH1A1KDM4E
SCHEMBL31145923 0.75 GPR139 (0.36) GPR139KMT2AKDM4EHSD17B10TDP1
SCHEMBL31145906 0.74 GPR183 (0.39) KMT2AADORA1ALDH1A1CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688748-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 — — US disclosed
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206339-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448369-B2 Quinolinone amide compounds and uses thereof TNNI3, TNNT2, COQ8A IDH1 318/4885GPR139 4135/4885P2RX7 2311/4885
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, COQ8A IDH1 318/4885GPR139 4135/4885P2RX7 2311/4885
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNT2, TNNI3, TNNC1 IDH1 1704/4885GPR139 4225/4885P2RX7 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback